Print

Prolacta Bioscience Secures Series D Funding from Health Evolution Partners  
11/3/2011 11:36:31 AM

MONROVIA, Calif.--(BUSINESS WIRE)--Prolacta Bioscience, the first and only company to offer human milk fortifier (HMF) made from 100% human breast milk for critically ill, premature infants, has announced that they have secured Series D funding from Health Evolution Partners (HEP). HEP invests in rapidly growing companies that are commercial leaders in the healthcare industry. The funding will be used primarily to fund a second facility and to support growth of Prolacta’s sales organization.
//-->